What biomarkers can reliably detect microglial priming states in living patients before neurodegeneration?

Biomarker Hypotheses for Detecting Microglial Priming States

Hypothesis 1: TSPO PET Kinetic Modeling for Priming State Discrimination

Title: Distinguishing primed from dystrophic microglia using TSPO PET with compartmental modeling

Mechanism: TSPO expression increases with microglial activation, but quantitative metrics (distribution volume VT, binding potential BP) may reveal distinct kinetic signatures between surveillance (baseline), primed (heightened sensitivity), and fully activated states. Primed microglia may show intermediate TSPO availability.

Target Gene/Protein/Pathway: TSPO (18 kDa translocator protein), peripheral benzodiazepine receptor

Supporting Evidence:

• TSPO PET elevation in AD, MS, and other neurodegenerative conditions (PMID: 29106766)
• Post-mortem studies showing TSPO+ microglia correlate with disease progression (PMID: 31862866)
• Failure of second-generation TSPO ligands highlights need for refined interpretation (PMID: 28595126)

Confidence: 0.65

Hypothesis 2: CSF YKL-40 as a Priming-Specific Chitinase Marker

Title: Cerebrospinal fluid YKL-40 identifies microglial priming prior to tau or amyloid biomarker changes

Mechanism: YKL-40 (chitinase-3-like protein 1, CHI3L1) is secreted by immunometabolic-trained microglia during the priming phase. Unlike acute activation markers, YKL-40 reflects chronic, adaptation-level microglial reprogramming characteristic of priming.

Target Gene/Protein/Pathway: CHI3L1/YKL-40, chitinase pathway

Supporting Evidence:

• Elevated CSF YKL-40 in pre-symptomatic familial AD (PMID: 29618783)
• YKL-40 increases before detectable neurodegeneration in dominantly inherited AD (PMID: 33788986)
• Astrocyte-microglial co-regulation of YKL-40 in neuroinflammation (PMID: 32160520)

Confidence: 0.72

Hypothesis 3: P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming

Title: P2X7 receptor PET identifies NLRP3 inflammasome-engaged primed microglia

Mechanism: Primed microglia exhibit "licensing" of the NLRP3 inflammasome, requiring a second trigger for full activation. P2X7R (ATP-gated ion channel) is specifically upregulated in primed microglia preparing for inflammasome assembly. P2X7R PET would selectively label the primed state.

Target Gene/Protein/Pathway: P2X7R (P2RX7), NLRP3 inflammasome, purinergic signaling

Supporting Evidence:

• P2X7R deletion or blockade prevents microglial priming in mouse models (PMID: 28465143)
• P2X7R expression correlates with disease severity in MS and ALS (PMID: 30181108)
• First-in-human P2X7R PET tracer (¹¹C-JNJ-54175446) demonstrates brain penetration (PMID: 31771992)

Confidence: 0.58

Hypothesis 4: Blood Monocyte Epigenetic Signature as Surrogate for Microglial Priming

Title: Peripheral blood monocyte ATAC-seq identifies microglial priming epigenetic landscape

Mechanism: Microglial priming involves trained immunity with persistent epigenetic reprogramming. Blood monocytes share ontogeny with microglia and may mirror central nervous system immunophenotypes through trained chromatin accessibility patterns, enabling peripheral biomarker access.

Target Gene/Protein/Pathway: Epigenetic landscape (ATAC-seq peaks), trained immunity genes (TLR4, NLRP3, IL1B regulatory regions)

Supporting Evidence:

• Epigenetic signatures in blood predict neurodegenerative disease progression (PMID: 34534167)
• Mouse models show parallel chromatin changes in microglia and bone marrow monocytes after systemic inflammation (PMID: 30651565)
• ChIP-seq identifies distinct microglial enhancer landscapes in AD (PMID: 29691402)

Confidence: 0.52

Hypothesis 5: CSF Soluble TREM2 Fragment Ratio as Priming State Indicator

Title: sTREM2 cleavage ratio distinguishes homeostatic from priming-phase microglia

Mechanism: TREM2 is expressed by disease-associated microglia (DAM). Soluble TREM2 (sTREM2) results from proteolytic shedding (ADAM10/17). The ratio of sTREM2 fragments (N-terminal vs. C-terminal) may reflect microglial activation state transitions, with specific patterns indicating priming.

Target Gene/Protein/Pathway: TREM2, ADAM10/17 proteases, TYROBP/DAP12 signaling

Supporting Evidence:

• CSF sTREM2 increases in early symptomatic AD (PMID: 27991925)
• TREM2 variants alter microglial response to amyloid plaques (PMID: 28165504)
• TREM2 shedding is regulated by activity and disease state (PMID: 30455459)

Confidence: 0.68

Hypothesis 6: Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin

Title: Combinatorial CSF biomarker algorithm identifies microglial priming preceding synaptic dysfunction

Mechanism: No single marker reliably distinguishes priming. A weighted algorithm combining a priming-specific marker (YKL-40), a microglial activation state marker (sTREM2), and a synaptic vulnerability marker (neurogranin) creates a composite fingerprint identifying the temporal window before neurodegeneration.

Target Gene/Protein/Pathway: CHI3L1, TREM2, NRGN, neuroinflammation-synapse crosstalk

Supporting Evidence:

• CSF YKL-40 and sTREM2 show distinct temporal patterns in AD (PMID: 32084334)
• Neurogranin reflects synaptic integrity and predicts progression (PMID: 29198979)
• Multi-marker models outperform single biomarkers for AD prediction (PMID: 30814620)

Confidence: 0.75

Hypothesis 7: CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Title: CX3CR1-targeted nanobody PET defines microglial homeostatic coverage and priming-induced retraction

Mechanism: CX3CL1-CX3CR1 signaling maintains microglial surveillance. Priming involves partial CX3CR1 downregulation and process retraction. CX3CR1-specific nanobody PET tracers (small size, high affinity) would quantify this morphological-functional shift as a priming biomarker.

Target Gene/Protein/Pathway: CX3CR1 (fractalkine receptor), CX3CL1/CX3CR1 axis

Supporting Evidence:

• CX3CR1 haploinsufficiency accelerates neurodegeneration in mouse models (PMID: 15308663)
• CX3CR1 expression decreases on microglia near amyloid plaques (PMID: 24415754)
• Nanobody-based PET tracers show superior brain penetration (PMID: 32316366)

Confidence: 0.48

Summary Table

| # | Biomarker | Modality | Confidence |
|---|-----------|----------|------------|
| 1 | TSPO PET kinetic modeling | Imaging | 0.65 |
| 2 | CSF YKL-40 | Fluid | 0.72 |
| 3 | P2X7R PET | Imaging | 0.58 |
| 4 | Blood monocyte ATAC-seq | Epigenetic | 0.52 |
| 5 | CSF sTREM2 fragment ratio | Fluid | 0.68 |
| 6 | Multi-analyte CSF panel | Fluid | 0.75 |
| 7 | CX3CR1 nanobody PET | Imaging | 0.48 |

Recommended Priority: Hypotheses 2, 6, and 5 represent near-term clinical translation opportunities using existing assay technologies. Hypothesis 7 offers the most mechanistically specific target but requires significant tracer development.

Critical Evaluation of Microglial Priming Biomarker Hypotheses

Hypothesis 1: TSPO PET Kinetic Modeling

Weak Links

Specificity Crisis. TSPO is expressed on microglia, astrocytes, endothelial cells, and infiltrating peripheral immune cells. TSPO PET measures a composite signal from heterogeneous cell populations, making it fundamentally unable to distinguish microglial-specific priming states. Post-mortem validations correlating TSPO+ cells with disease progression cannot disentangle this cellular ambiguity for in vivo application.

The "Intermediate Signal" Problem. The hypothesis proposes that primed microglia show "intermediate TSPO availability" between surveillance and full activation. This is unfalsifiable without an independent ground truth for priming states. TSPO is a continuous, graded signal—how does one operationally define and detect "intermediate" in a manner that is reproducible across scanners, subjects, and timepoints?

Second-Generation Ligand Failure as Fatal Counter-Evidence. The supporting evidence acknowledges that second-generation TSPO ligands have already failed, but this failure is underweighted. The clinical failure signals fundamental problems with TSPO as a target: either the biology is more complex than assumed, or TSPO does not robustly report the states we care about. Proposing refined kinetic modeling on a failed target base lacks scientific justification.

Genetic Polymorphisms. TSPO binding affinity varies by rs6971 polymorphism, requiring genotype stratification. This adds substantial noise and complexity, particularly in longitudinal studies where genotype remains constant but scanner, tracer batch, and analysis pipelines evolve.

Falsifying Experiments

Revised Confidence: 0.45

Hypothesis 2: CSF YKL-40

Weak Links

Cellular Origin Ambiguity. YKL-40 is produced by astrocytes, microglia, and infiltrating immune cells. The supporting evidence acknowledges "astrocyte-microglial co-regulation," but this fundamentally undermines specificity. Elevated CSF YKL-40 could reflect astrocyte reactivity, microglial priming, or systemic inflammation with monocyte infiltration—these are mechanistically distinct states.

Specificity Across Neurodegenerative Diseases. YKL-40 is elevated in traumatic brain injury, stroke, multiple sclerosis, and likely most conditions with chronic neuroinflammation. The hypothesis relies on evidence from dominantly inherited familial AD (DIAN), which represents a specific, genetically determined trajectory. Sporadic late-onset AD (LOAD) has different inflammatory dynamics, and the temporal relationship between YKL-40 and pathology may not generalize.

Temporal Specificity. The hypothesis claims YKL-40 increases "before detectable neurodegeneration," but the cited evidence (PMID: 33788986) shows elevation in pre-symptomatic familial AD—which has a fixed, amyloid-driven trajectory. In sporadic LOAD, amyloid elevation precedes symptoms by 15-20 years, and inflammatory markers may have different temporal relationships. YKL-40 elevation may correlate with pre-existing amyloid burden rather than specifically marking a "priming window."

High Inter-Individual Variability. YKL-40 has substantial baseline variability influenced by age, systemic inflammation, infection, and metabolic status. Without careful exclusion criteria and large cohorts, ROC-derived thresholds will not generalize.

Falsifying Experiments

Revised Confidence: 0.60

Hypothesis 3: P2X7R PET

Weak Links

Tracer Development Stage. The hypothesis cites a "first-in-human" tracer study (PMID: 31771992) but presents no evidence that this tracer:

• Has adequate specific-to-nonspecific binding ratio in human brain
• Can detect physiologically relevant P2X7R expression differences
• Is specific to microglial P2X7R versus neuronal or peripheral expression

Non-Microglial P2X7R Expression. P2X7R is expressed on neurons, astrocytes, oligodendrocytes, and peripheral immune cells. A P2X7R PET signal cannot be attributed to microglia without microglial-specific validation.

Mechanistic Specificity Question. The "licensing" concept—that primed microglia require a second trigger for full activation—is not universally accepted. Some priming models do not involve NLRP3, and the P2X7R-NLRP3-priming axis may be context-specific (e.g., specific to certain inflammatory challenges). The hypothesis assumes this axis is central to AD-relevant microglial priming.

Species Differences. P2X7R pharmacology and expression patterns differ between rodents and humans. Rodent studies showing that P2X7R deletion prevents priming may not translate.

Falsifying Experiments

Revised Confidence: 0.35

Hypothesis 4: Blood Monocyte ATAC-seq

Weak Links

The Blood-CNS Concordance Assumption. This hypothesis rests on an unproven assumption: that blood monocyte epigenetic states mirror CNS microglial states. While microglia and monocytes share a common myeloid progenitor, the blood-brain barrier creates fundamentally different environmental pressures. Epigenetic programming in the CNS (by amyloid, tau, neuronal signals) may not be replicated in circulating monocytes exposed to a completely different cytokine milieu.

Supporting Evidence Does Not Establish the Core Claim. The cited mouse study (PMID: 30651565) showing "parallel chromatin changes" requires scrutiny. Systemic inflammation causes both microglia and monocytes to activate—this parallel does not establish that blood monocytes report disease-specific microglial states in chronic neurodegeneration. The evidence suggests shared response to acute inflammation, not disease-specific chronic reprogramming.

Epigenetic Noise. ATAC-seq signals are influenced by medication, diet, diurnal variation, smoking, metabolic status, and circadian rhythms. Isolating an AD-specific microglial priming signal from this noise in peripheral cells is highly uncertain.

The Brain-Microglia Problem. Even if peripheral epigenetic signatures could report on CNS states, the critical measurement is not the epigenetic state of the CNS but the functional state of microglia. Epigenetic changes may precede, follow, or be orthogonal to functional microglial states.

Falsifying Experiments

Revised Confidence: 0.40

Hypothesis 5: CSF sTREM2 Fragment Ratio

Weak Links

The Proposed Assay Does Not Exist. The hypothesis proposes developing a mass spectrometry assay for "site-specific TREM2 fragments" to distinguish N-terminal from C-terminal fragments. This is a conceptual/technological proposal, not an existing biomarker. Substantial assay development (2-5 years) would be required before any validation. Confidence in a non-existent assay is inherently limited.

Biological Basis Uncertain. The hypothesis claims that specific sTREM2 fragment ratios "indicate priming." However:

• The mechanism of TREM2 shedding (ADAM10/17) is regulated by multiple pathways
• The relationship between fragment ratios and microglial functional states has not been established
• Whether different fragments reflect different cellular states versus different protease environments is unknown

Complex Temporal Dynamics. sTREM2 shows a biphasic pattern in AD: elevation in early disease, followed by decline. The fragment ratio hypothesis does not address how this temporal complexity maps onto priming states, which may themselves be transient.

Falsifying Experiments

Revised Confidence: 0.55

Hypothesis 6: Integrated Multi-Analyte CSF Panel

Weak Links

Inherits All Component Weaknesses. The multi-marker approach sounds robust, but it propagates the limitations of YKL-40, sTREM2, and neurogranin. If YKL-40 does not specifically reflect microglial priming, the composite index will not either—combining nonspecific markers does not create specificity.

Overfitting Risk. Elastic net regression with 12 markers in discovery cohorts and validation in "equivalent cohorts" (likely similarly selected) creates substantial overfitting risk. The derived "microglial priming index" may be an artifact of the training data that fails to generalize.

"Priming Index" Is Not a Biological State. The composite score creates a continuous variable from what may be heterogeneous biological processes. This mathematical construct may not correspond to a coherent microglial priming state—it could be a statistical artifact.

Added Multiple Comparison Burden. Testing 12 markers increases the probability of false positives and requires stringent correction. The

Feasibility Assessment: Microglial Priming Biomarkers

Executive Summary

The debate identified a fundamental translational gap: even validated microglial targets remain therapeutically inaccessible without biomarkers to define the treatment-eligible population. The biomarker hypotheses range from near-term clinical feasibility (Hypotheses 2, 5, 6) to speculative targets requiring extensive development (Hypotheses 4, 7). The integration of clinical pragmatism with mechanistic specificity determines which hypotheses merit prioritization.

Comparative Feasibility Matrix

| Hypothesis | Biomarker Feasibility | Clinical Translation Risk | Development Timeline | Estimated Cost (USD) | Overall Priority |
|------------|---------------------|--------------------------|---------------------|---------------------|------------------|
| 1: TSPO PET Kinetic | Moderate (technology exists) | High (specificity failure) | 3-5 years | $15-25M | Low |
| 2: CSF YKL-40 | High (validated assays) | Moderate (cell-type ambiguity) | 2-3 years | $5-10M | High |
| 3: P2X7R PET | Low (tracer not qualified) | High (multiple unknowns) | 5-8 years | $30-50M | Low |
| 4: Blood ATAC-seq | Low (fundamental assumptions untested) | Very High | 4-7 years | $20-40M | Drop |
| 5: sTREM2 Fragment Ratio | Moderate (assay requires development) | Moderate (biological uncertainty) | 3-5 years | $10-20M | Medium-High |
| 6: Multi-Analyte CSF Panel | High (existing platforms) | Low-Moderate | 2-3 years | $8-15M | Highest |
| 7: CX3CR1 Nanobody PET | Very Low (no validated tracer) | High (multiple unknowns) | 6-10 years | $40-70M | Research Only |

Hypothesis-by-Hypothesis Assessment

Hypothesis 2: CSF YKL-40

Druggability: Not directly applicable (YKL-40 is a biomarker, not a drug target). However, YKL-40 elevation identifies patients with active neuroinflammatory processes that could be targeted with existing anti-inflammatory or microglial-modulating agents (e.g., TREM2 agonists, NLRP3 inhibitors).

Biomarkers/Model Systems:

• Assay technology: ELISA and Luminex platforms exist and are CLIA-validated. Commercial assays available from Quanterix, Rugen bio, and others.
• Sample requirements: 0.5-1mL CSF per measurement. Longitudinal sampling feasible.
• Study populations: DIAN cohort, Biofinder, AIBL, and similar cohorts have existing baseline samples. Pre-symptomatic LOAD enrichment requires APOE4+ carriers with parental AD history.
• Critical limitation: The cell-type ambiguity (astrocyte vs. microglia) cannot be resolved without direct histological correlation. Mouse models with cell-type-specific YKL-40 knockout are essential for validation.

• Regulatory pathway: Biomarker qualification through EMA/PPO or FDA Biomarker Qualification Program is feasible but requires prospective validation in independent cohorts.
• The specificity concern for non-AD neurodegeneration must be addressed. If YKL-40 is elevated in pure tauopathies at similar levels, it cannot distinguish AD-specific microglial priming from general neuroinflammatory responses.
• Defining the "priming-predictive threshold" requires longitudinal outcome data (cognitive decline, conversion to MCI) over 3-5 years minimum.

• CSF collection via lumbar puncture carries <1% risk of post-LP headache and <0.1% serious complications. Acceptable for clinical research, but repeated sampling (quarterly/biannual) increases cumulative risk.
• No radiation exposure, enabling frequent longitudinal sampling.

• Assay optimization and harmonization: 6-12 months
• Retrospective validation in existing cohorts: 12-18 months
• Prospective validation with cognitive endpoints: 36-60 months
• Total realistic timeline: 3-4 years to validation, 5-6 years to qualification
• Estimated cost: $5-10M for validation studies, $15-25M to qualification

Hypothesis 5: CSF sTREM2 Fragment Ratio

Druggability: TREM2 is a high-value therapeutic target with active development programs (Biogen, AbbVie, Denali). The fragment ratio biomarker would enable patient stratification for TREM2-targeted therapies (agonists, ectodomain stabilizers). The biomarker itself is not druggable, but it directly enables druggable target utilization.

Biomarkers/Model Systems:

• Assay technology: Must be developed de novo. Requires mass spectrometry (LC-MS/MS) capable of distinguishing N-terminal and C-terminal TREM2 fragments at femtomolar sensitivity in CSF. Development timeline: 1-2 years for assay establishment.
• Current state: Commercially available sTREM2 ELISAs measure total sTREM2, not fragment-specific ratios. The site-specific fragmentation hypothesis is biologically plausible based on ADAM10/17 cleavage biology but requires direct experimental validation.
• Critical experiments: Mass spectrometry characterization of all TREM2 fragments in human CSF from post-mortem cases with confirmed microglial morphology (Iba1+ CD68+ scoring). This linking study is essential before any biomarker development proceeds.

• The biphasic sTREM2 pattern (elevation in early AD, decline in late stages) adds temporal complexity. Fragment ratios may track differently across disease stages, requiring careful longitudinal characterization.
• TREM2 R47H variant (high-impact AD risk allele) provides a natural experiment—carriers have altered TREM2 function and likely altered shedding. Comparing fragment ratios between carriers and non-carriers could establish biological correlates.
• Multi-cell source (microglia, macrophages, dendritic cells) is a concern, but in the absence of BBB disruption, CSF sTREM2 primarily reflects CNS sources.

• Same as Hypothesis 2: lumbar puncture risk profile acceptable for research context.
• Development of fragment-specific antibodies for immunoassays carries no patient risk once assay is established.

• Assay development: 18-24 months
• Fragment characterization linking studies: 12-18 months
• Validation in discovery cohort: 18-24 months
• Prospective validation: 36-48 months
• Total realistic timeline: 4-5 years to validated biomarker, 6-7 years to qualification
• Estimated cost: $10-20M for development and validation, $25-35M to qualification

Hypothesis 6: Integrated Multi-Analyte CSF Panel

Druggability: Not directly applicable. This is an enrichment/diagnostic strategy rather than a target-specific biomarker. However, by identifying patients in the microglial priming window, it enables deployment of multiple drug candidates (TREM2 agonists, NLRP3 inhibitors, CSF1R antagonists, anti-inflammatory agents). The biomarker enables rather than constitutes druggability.

Biomarkers/Model Systems:

• Assay technology: Luminex-based multiplex panels are commercially available. Biofinder (Hoffmann-La Roche) and equivalent platforms have established inflammatory biomarker panels including YKL-40, sTREM2, neurogranin, and additional markers (VILIP-1, CHI3L1, MCP-1, IL-6, TNF-α).
• Strength: Multi-marker approach provides statistical robustness against individual marker limitations. YKL-40 elevation (astrocytes + microglia) + sTREM2 elevation (microglial activation) + neurogranin decline (synaptic vulnerability) creates a composite signature that may converge on the priming-to-neurodegeneration transition.
• Limitation: The approach inherits component weaknesses. If YKL-40 does not specifically reflect microglial priming, the composite index may reflect a different biological state (e.g., astrocyte reactivity with secondary microglial response).
• Model systems: In vitro iPSC-derived microglia (iMG) exposed to amyloid/tau can provide mechanistic validation. iMG secretome can be compared against CSF biomarker profiles.

• Overfitting risk: 12 markers with elastic net regression in discovery cohort requires rigorous validation in independent, demographically matched cohorts. External validation across multiple sites is essential.
• The "microglial priming index" as a continuous variable requires clinical outcome correlation. ROC analysis for categorical outcomes (cognitive decline yes/no) may be more regulatory-friendly than continuous scores.
• Multi-center implementation: Luminex has inter-laboratory variability; assay harmonization and standardization across sites is required before multi-center trials.
• Regulatory pathway: Biomarker panel qualification similar to CSF amyloid/tau panels. FDA/EMA acceptance of composite scores requires established clinical utility (prediction of treatment response or clinical outcome).

• Same lumbar puncture risk profile as Hypotheses 2 and 5.
• No additional risk beyond component biomarkers.
• Advantage: a single CSF draw provides all markers, minimizing patient burden versus sequential testing.

• Assay optimization and harmonization: 6-12 months
• Discovery cohort analysis: 12-18 months
• Machine learning derivation of composite index: 6-12 months
• Independent validation: 18-24 months
• Prospective validation with clinical endpoints: 36-48 months
• Total realistic timeline: 3-4 years to validated panel, 5-6 years to regulatory qualification
• Estimated cost: $8-15M for development and internal validation, $20-35M to qualification with clinical outcome correlation

Hypothesis 1: TSPO PET Kinetic Modeling

Druggability: TSPO is not an attractive drug target for microglial priming (benzodiazepine site ligands have psychotropic effects). However, TSPO PET could identify patients with elevated neuroinflammation for enrollment in anti-inflammatory trials (e.g., NSAIDs, colchicine, anti-IL-6 trials).

Biomarkers/Model Systems:

• PET technology exists and is clinically available at academic centers with radiochemistry infrastructure.
• Kinetic modeling (2-tissue compartment) is computationally established but requires standardized acquisition protocols, metabolite correction, and reference tissue selection across sites.
• The specificity problem (TSPO on microglia + astrocytes + endothelial + peripheral immune) is fundamental. TSPO PET measures "neuroinflammation" not "microglial priming."
• rs6971 genotyping required for subject stratification. Third-generation TSPO ligands with lower affinity variation are in development but not clinically validated.
• Mitigation: Combine TSPO PET (total neuroinflammation) with CSF YKL-40 (specific marker) to triangulate microglial contribution to signal. TSPO PET + CSF YKL-40 correlation could establish microglial-specific component.

• Radiation exposure: ~2-5 mSv per ¹¹C-PBR28 or ¹⁸F-GE180 scan (comparable to CT chest). Limits frequency of longitudinal imaging.
• Scanner variability: PET quantification depends on scanner, reconstruction algorithm, and partial volume effects. Multi-site studies require careful harmonization.
• Post-mortem correlation: Essential for validation but introduces survival bias (advanced patients more likely to donate tissue).

• PET radiation exposure acceptable for clinical research but cumulative dose concerns for repeated imaging.
• Tracer administration: ¹¹C tracers have 20-minute half-life (limited radiation); ¹⁸F tracers have 110-minute half-life (higher dose but distributed synthesis).

• Kinetic modeling pipeline establishment: 12-18 months
• Single-site validation with CSF correlation: 18-24 months
• Multi-site harmonization: 12-18 months
• Prospective validation with clinical endpoints: 36-48 months
• Total realistic timeline: 4-5 years to validated imaging biomarker
• Estimated cost: $15-25M for imaging infrastructure and validation studies

Hypothesis 3: P2X7R PET

Druggability: High. P2X7R antagonists are in clinical development for CNS indications (Biogen, Roche, Pfizer have programs). P2X7R PET tracer could enable target engagement studies and patient selection for P2X7R-targeted therapies.

Biomarkers/Model Systems:

• First-in-human tracer (¹¹C-JNJ-54175446) demonstrated brain penetration but:
• Specific-to-nonspecific binding ratio not established as adequate
• Microglial specificity not validated
• Sensitivity to physiologically relevant expression differences unknown
• Tracer development stage: preclinical to early clinical translation. Substantial work required before qualification.
• Validation against microglial-specific markers (CX3CR1 nanobody, TMEM119 PET when available) is essential.